No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
WW, ATNM and XTIA Are Among Pre Market Gainers
Repligen Appoints Maggie A. Pax to Board of Directors
ATyr Pharma Full Year 2023 Earnings: Revenues Disappoint
ATyr Pharma Is Maintained at Outperform by RBC Capital
ATyr Pharma Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Outperform on ATyr Pharma, Lowers Price Target to $16
RBC Capital analyst Gregory Renza maintains aTyr Pharma (NASDAQ:LIFE) with a Outperform and lowers the price target from $19 to $16.
ATyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress
No Data